J-Pharma receives AMED grant approval of up to ¥1.5 billion
The award supports the Beacon-BTC trial of an investigational treatment for biliary tract cancer.
J-Pharma announced on 30 October 2026 that the Japan Agency for Medical Research and Development (AMED) had approved its ¥1.5 billion subsidy application under the GRiT programme. The funded project began on 29 October and is scheduled to run through 31 December 2028.
The non-dilutive support is intended to advance Part A of the global Phase 3 Beacon-BTC trial of nanvuranlat, a LAT1 inhibitor being developed for biliary tract cancer. The approval follows the project’s selection in early October and establishes the subsidy ceiling; it does not represent an equity investment.
Use of funds
Global Phase 3 Beacon-BTC Part A trial of nanvuranlat for biliary tract cancer